Evidence map›Paper›PMID 37723068›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2023

[Real-world study on the efficacy and safety of first-line antiviral therapy for chronic hepatitis B].

C D Chang, C Dong, S X Zhao, X W Yuan, X X Zhang, D D Zhao, Y Dou, Y M Nan

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. [Comparison of the effects of tenofovir amibufenamide and tenofovir alafenamide on lipid metabolism in the body].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
  5. [Real-world study of tenofovir amibufenamide in the treatment of patients with hepatitis B cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

C D ChangDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Provincial Key Laboratory of study on Mechanism of Hepatic Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China.
C DongDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Provincial Key Laboratory of study on Mechanism of Hepatic Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China.
S X ZhaoDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Provincial Key Laboratory of study on Mechanism of Hepatic Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China.
X W YuanDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Provincial Key Laboratory of study on Mechanism of Hepatic Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China.
X X ZhangDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Provincial Key Laboratory of study on Mechanism of Hepatic Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China.
D D ZhaoDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Provincial Key Laboratory of study on Mechanism of Hepatic Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China.
Y DouDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Provincial Key Laboratory of study on Mechanism of Hepatic Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China.
Y M NanDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Provincial Key Laboratory of study on Mechanism of Hepatic Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China.

Funding

The Key Research and Development Program of Hebei Province 19277779DThe Program of Introduce International Intelligence of Hebei Province
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antiviral AgentsHepatitis B, ChronicHumansPhosphorusTenofovirViremiaAntiviral AgentsPhosphorusTenofovirChronic hepatitis BEfficacyEntecavirSafetyTenofovir alafenamide fumarateTenofovir disoproxil fumarate

Identifiers

PMID37723068
PMCPMC12814701

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.